{"disease":{"id":"non-infectious-uveitis","name":"non infectious uveitis"},"drugs":{"marketed":[{"drug_id":"abrilada","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"abrilada","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrilada","generic_name":"Adalimumab-Afzb","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor necrosis factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":"10191","mechanism":"Adalimumab-afzb binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"dexamethasone","indication_name":"Non-infectious Posterior Uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"adalimumab","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Humira","generic_name":"ADALIMUMAB","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Tumor Necrosis Factor-alpha (TNF-alpha)","drug_class":"TNF blocker","quality_score":10,"revenue":null,"mechanism":"Adalimumab binds TNF-alpha and blocks interaction with p55 and p75 cell surface receptors."},{"drug_id":"adalimumab-adbm","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"adalimumab-adbm","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"CYLTEZO","generic_name":"ADALIMUMAB-ADBM","company_name":"BOEHRINGER INGELHEIM","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"humira","indication_name":"Non-infectious anterior uveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"humira","indication_name":"Non-infectious intermediate, posterior and panuveitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Humira","company_name":"Sohag University","drug_phase":"marketed","molecular_target":"Tumor necrosis factor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":9,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06686641","title":"Incidence of Macular Edema in a Uveitis Population","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1550,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT02951975","title":"Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye","phase":"","overall_status":"TERMINATED","enrollment_count":246,"lead_sponsor_name":"Allergan","has_results":false},{"nct_id":"NCT07262437","title":"Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":220,"lead_sponsor_name":"University of Milan","has_results":false},{"nct_id":"NCT04018599","title":"Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":216,"lead_sponsor_name":"Fresenius Kabi SwissBioSim GmbH","has_results":false},{"nct_id":"NCT03339102","title":"Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients","phase":"","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT07136805","title":"A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"VivaVision Biotech, Inc","has_results":false},{"nct_id":"NCT03711929","title":"LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":145,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT05042609","title":"A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":142,"lead_sponsor_name":"Tarsier Pharma","has_results":false},{"nct_id":"NCT01694186","title":"Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03131154","title":"SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":123,"lead_sponsor_name":"Aldeyra Therapeutics, Inc.","has_results":true},{"nct_id":"NCT06258915","title":"Treatment FOr Corticosteroid Dependent UveitiS","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT06585670","title":"Mindfulness Approach for Reducing Anxiety and Gloom in Ocular Inflammatory Diseases","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT05414201","title":"A Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Participants Requiring High Dose Corticosteroids for Active Non-Infectious Intermediate, Posterior, or Pan-Uveitis","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT03207815","title":"Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":74,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT07218770","title":"A Study of REGN7041 for Active Noninfectious Uveitis in Adult Participants","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02251938","title":"A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Santen Inc.","has_results":true},{"nct_id":"NCT07480291","title":"Periodontal Status and Cytokine Levels in Patients With Non-Infectious Uveitis","phase":"","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Selcuk University","has_results":false},{"nct_id":"NCT05953688","title":"POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"Alumis Inc","has_results":false},{"nct_id":"NCT04426734","title":"Evaluation of DEXTENZA in the Management of Pain and Inflammation in Patients With Anterior Uveitis Compared to Standard of Care Topical Corticosteroids","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"New England Retina Associates","has_results":false},{"nct_id":"NCT02748512","title":"Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"EyePoint Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05523765","title":"A Study of Brepocitinib in Adults With Active Non-Infectious Non-Anterior Uveitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Priovant Therapeutics, Inc.","has_results":false},{"nct_id":"NCT01526889","title":"Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT06539481","title":"Open Label Trial Studying the Safety and Effectiveness of ILUVIEN® (190μg) in Children and Adolescents, Who Have Recurrent Non-infectious Uveitis Affecting the Posterior Segment of the Eye.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Alimera Sciences","has_results":false},{"nct_id":"NCT04354909","title":"Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT07145008","title":"Suprachoroidal Triamcinolone in Macular Edema for Patients With Non-Infectious Uveitis Resistant to Subtenon Triamcinolon","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"University of Baghdad","has_results":false},{"nct_id":"NCT04222712","title":"A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Tarsier Pharma","has_results":true},{"nct_id":"NCT03308045","title":"Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Eyevensys","has_results":false},{"nct_id":"NCT04126850","title":"Pilot Project: The Amplicon and Metatranscriptomic Study of Intra and Extra Intestinal Microbiome in Non-infectious Uveitis Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Fakultas Kedokteran Universitas Indonesia","has_results":false},{"nct_id":"NCT00326508","title":"Combination Daclizumab/Denileukin Diftitox to Treat Uveitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT04207983","title":"A 48 Week Study to Evaluate the Efficacy and Safety of Two (2) EYS606 Treatment Regimens in Subjects With Active Chronic Non-infectious Uveitis (CNIU)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Eyevensys","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}